Clinical trials: Disease or Disorder
Hodgkin Lymphoma, Adult
Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma
The standard chemotherapy for Hodgkin lymphoma is called ABVD which is a combination of 4 chemotherapy drugs (doxorubicin, bleomycin, vinblastine, and dacarbazine).
- Trial name
- NCT01578967
- Testing
- Brentuximab vedotin, ABVD
- Where
- 6 sites in United States
- Volunteers
- 41 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Angimis Atherectomy System is Indicated for CTO, Balloon Failure and ISR in Coronary Arteries Disease
A Prospective, Multicenter, Two-cohorts, Single Arm Study Evaluating Safety, Effectiveness and Performance of Angimis Atherectomy System for the Treatment of Non-crossable and/or Non-dilatablE Lesions in CorONary Arteries Disease (NEON Study).
NEON study is a prospective, multicenter, two-cohorts, single arm study evaluating safety, effectiveness and performance of Angimis Atherectomy System for the treatment of Non-crossable and/or Non-dilatable in Coronary Arteries…
- Trial name
- NEON (NCT07743528)
- Testing
- Adult patient population who have been diagnosed with coronary artery disease with non-crossable and/or non-dilatable lesion which requiring the treatment of PCI
- Volunteers
- 123 people
- Sponsor
- Shenzhen Tonglu Technology Co., Ltd
MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus)
A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus)
This is a parallel arm non-randomized dose-escalation, open-label basket exploratory phase 1 clinical trial where Mitochondrial encephalopathy, lactic acidosis, stroke-like episodes (MELAS) and Leber's hereditary optic…
- Trial name
- NCT06792500
- Testing
- Glycerol Tributyrate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- George Washington University
Leukemia, Myeloid, Chronic
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)
The goal of this clinical research study is to learn if giving PEG-Alpha Interferon (PEG-Intron) and Sargramostim (GM-CSF) to patients receiving treatment with high dose Gleevec (imatinib mesylate) is more effective in treating…
- Trial name
- NCT00050531
- Testing
- Gleevec, Peg-alpha interferon (Peg-Intron), Sargramostim (GM-CSF)
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma, Brain Tumor
ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids
ARISTOCRAT is a phase II, multi-centre, double-blind, placebo-controlled, randomised trial to compare the cannabinoid Nabiximols with placebo in patients with recurrent MGMT methylated glioblastoma (GBM) treated with temozolomide…
- Conditions
- Glioblastoma, Brain Tumor, Cannabis, Brain Tumor, Recurrent
- Trial name
- ARISTOCRAT (NCT05629702)
- Testing
- Nabiximols, Temozolomide
- Where
- 17 sites in United Kingdom
- Volunteers
- 122 people
- Sponsor
- University of Birmingham
Hodgkin's Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL)
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
The primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in participants treated with…
- Trial name
- NCT04875195
- Testing
- Pembrolizumab
- Where
- 27 sites in United States, Brazil and 9 more
- Volunteers
- 66 people
- Sponsor
- Merck Sharp & Dohme LLC
Optic Neuritis
Pupillometry Dynamic Measures in Patients Without Ocular or Neurological Disease
Retrobulbar optic neuritis (NORB) is the damage to the optic nerve caused by inflammation. It causes a rapidly progressive and painful visual loss, often among young subjects.
- Trial name
- PCT (NCT02894281)
- Testing
- pupillary light reflex
- Where
- France
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Endometrial Cancer
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment…
- Trial name
- DE-01 (NCT06989112)
- Testing
- Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab
- Where
- 257 sites in United States, Australia and 21 more
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Acute Myeloid Leukemia, Relapsed, Adult
CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
This study is to investigate the therapeutic efficacy and side effect of chidamide, decitabine combined with priming IAG regimen for relapsed or refractroy acute myeloid leukemia
- Trial name
- NCT03985007
- Testing
- CDIAG regimen
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Lung Cancer, Cancer of Lymph Node
Strategy of Surgical Resection With Adjuvant Therapy for IIIA NSCLC and N2 Disease Only in Subaortic or Paraaortic Level
The purpose of this study is to identify the treatment outcomes of surgical resection with sequential adjuvant chemotherapy and radiotherapy in patients with stage IIIA non-small cell lung cancer and N2 disease at only the sub…
- Conditions
- Lung Cancer, Cancer of Lymph Node, Effects of Chemotherapy, Surgery
- Trial name
- NCT02555592
- Testing
- Primary surgical resection with sequential adjuvant therapy
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Pusan National University Hospital
Frailty, Coronary Artery Disease
Funcional Recovery After Minithoracotomy or Sternotomy for CABG in Frail Patients
Frailty is a major predictor of adverse outcomes following coronary artery bypass grafting (CABG), being associated with increased postoperative complications, prolonged hospitalization, delayed functional recovery, and reduced…
- Conditions
- Frailty, Coronary Artery Disease, Coronary Artery Bypass Graft (CABG)
- Trial name
- MINIFRAGILE (NCT07742475)
- Testing
- Minimally Invasive Coronary Artery Bypass Grafting (MICS-CABG), Conventional Coronary Artery Bypass Grafting (Median Sternotomy)
- Volunteers
- 194 people
- Sponsor
- University of Sao Paulo General Hospital
Bipolar Disorder, Manic
Study of Lumateperone in the Treatment of Patients With Bipolar Mania
This is a multicenter, randomized, double-blind, placebo-controlled, study in the acute treatment of patients with a diagnosis of bipolar I disorder with manic episodes or manic episodes with mixed features (bipolar mania), with…
- Trial name
- NCT06462612
- Testing
- Lumateperone
- Where
- 35 sites in United States, Bulgaria and 2 more
- Volunteers
- 351 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Recurrent or Metastatic Nasopharyngeal Carcinoma
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma
The objective of this study is to assess the safety, efficacy, pharmacokinetics, and immunogenicity of MRG003 in patients with recurrent metastatic nasopharyngeal carcinoma.
- Trial name
- NCT05126719
- Testing
- MRG003, Capecitabine tablets, Docetaxel injection
- Where
- 23 sites in China
- Volunteers
- 238 people
- Sponsor
- Lepu Biopharma Co., Ltd.
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation
The Drugs Controller General of India (DCGI) has granted approval for Asciminib film-coated 40 mg tablets on 20 Oct 2023 with the condition to perform a Phase IV clinical study in Indian patients with Philadelphia…
- Trial name
- ASC4INDIA (NCT06427811)
- Testing
- Asciminib
- Where
- 10 sites in India
- Volunteers
- 85 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myeloid Leukemia (CML)
Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
The objective of this Phase II study is to assess the potential of asciminib in managing CML-CP or CML-AP in patient carrying the T315I mutation.
- Trial name
- ASC4TARGET (NCT06514534)
- Testing
- ABL001/Asciminib
- Where
- 6 sites in France
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Artery Disease
Both Exercise and Adenosine Stress Testing
The purpose of this study is to compare the 2-year cardiac outcomes for women with limited exercise capability based on the resuls of either pharmacological stress myocardial perfusion imaging or a combined protocol that…
- Trial name
- NCT00200629
- Testing
- Adenosine SPECT myocardial perfusion imaging, Combined adenosine / exercise SPECT myocardial perfusion imaging
- Where
- 20 sites in United States
- Volunteers
- 200 people
- Sponsor
- Midwest Heart Foundation
IrAE, Hematologic Disorder
Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer
This study is a single-arm clinical trial designed to evaluate the safety and efficacy of golidocitinib in patients with refractory, immune-related hematologic toxicity in advanced lung cancer.
- Conditions
- IrAE, Hematologic Disorder, Lung Cancer (Locally Advanced or Metastatic)
- Trial name
- JACKPOT22 (NCT07303881)
- Testing
- golidocitinib
- Where
- China
- Volunteers
- 16 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Gastrointestinal Stromal Tumor
Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
A phase IIIb study of patients with gastrointestinal stromal tumors who have had progressive disease while on 400 mg imatinib. Patients will be randomly assigned to either sunitinib 37.5 mg daily or imatinib 800 mg daily.
- Trial name
- NCT00372567
- Testing
- sunitinib malate, imatinib mesylate
- Where
- 25 sites in United States, Germany and 5 more
- Volunteers
- 69 people
- Sponsor
- Pfizer
Dementia Associated With Parkinson's Disease, Dementia With Lewy Bodies
Efficacy and Safety of Memantine for Parkinson's Disease Dementia (PDD) and Dementia With Lewy Bodies (DLB)
A 24-week placebo-controlled parallel group multicentre trial to study the safety and efficacy of memantine in patients with dementia associated with Parkinson's disease and dementia with Lewy bodies.
- Trial name
- MEMPDD (NCT00630500)
- Testing
- Memantine
- Where
- 4 sites in Norway, Sweden and 1 more
- Volunteers
- 75 people
- Sponsor
- Helse Stavanger HF
Morbid Obesity, Hypertension
Prevention of Coronary Heart Disease in Morbidly Obese Patients
The changes in risks of developing coronary heart disease in patients with morbid obesity after different weight loss interventions have not been extensively studied.
- Conditions
- Morbid Obesity, Hypertension, Type 2 DM, Obstructive Sleep Apnea
- Trial name
- SphCor (NCT00626964)
- Testing
- Bariatric Surgery, Conservative Treatment:
- Where
- Norway
- Volunteers
- 200 people
- Sponsor
- The Hospital of Vestfold
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.